Skip to main content
TipRanks
Go Ultimate75% OFF

Valiant Laboratories Ltd. (VALIANTLAB) AI Stock Analysis

0 Followers
IN:VALIANTLAB

Valiant Laboratories Ltd.

(NSE:VALIANTLAB)

Select Model
Rating:56Neutral
Price Target:INR 106.00â–²(2.66% Upside)
Action:reiterated
Date:09/10/26

The overall score is constrained by poor financial fundamentals, including negative cash flows and margins, and an expensive valuation with a high P/E ratio. However, strong bullish technical momentum significantly lifts the score, suggesting the market is pricing in a future turnaround that has not yet materialized in the financials.

Positive Factors
FY2026 Revenue ReboundThe FY2026 revenue recovery demonstrates that the company retains the ability to generate substantial API sales after a period of contraction. If this rebound is sustained, it can improve operating scale, support customer continuity, and provide a foundation for restoring profitability.
Negative Factors
Persistent LossesThe shift from profitability to losses indicates that the company’s current revenue base is not translating into dependable earnings. Persistent losses can weaken internal funding capacity, reduce returns on the equity base, and make future performance more sensitive to operating improvements.

Valiant Laboratories Ltd. (VALIANTLAB) vs. iShares MSCI India ETF (INDA)

-50%-25%0%25%50%75%100%IN:VALIANTLAB+33.74%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 5.48B
Dividend Yield
―
Average Volume (3M)
15.14K
Price to Earnings (P/E)
33.8
Beta (1Y)
0.27
Revenue Growth
102.37%
EPS Growth
176.45%
Country
India
Employees
84
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Valiant Laboratories Ltd. Business Overview & Revenue Model

Company Description

Valiant Laboratories Limited, an India-based company, specializes in the production of active pharmaceutical ingredients (APIs) and bulk drugs, serving both domestic and international markets. Its primary product is paracetamol, manufactured in vario...

How the Company Makes Money

Valiant Laboratories Ltd. makes money primarily by manufacturing and selling active pharmaceutical ingredients (APIs) to customers in the pharmaceutical supply chain (such as finished-dosage manufacturers and formulators). Its core revenue stream is...

Valiant Laboratories Ltd. Financial Statement Overview

Summary

Financial performance is weak. The Income Statement (Score 30) shows margin compression and net losses, and Cash Flow (Score 25) is deeply negative, raising liquidity concerns. These are partially offset by a solid Balance Sheet (Score 75) with low debt. Overall, profitability and cash generation are significant drags.

Income Statement

30Negative

Balance Sheet

75Positive

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue3.77B2.37B1.39B1.82B3.34B2.92B
Gross Profit731.87M272.66M222.17M115.76M390.07M523.21M
EBITDA385.24M87.11M7.55M-84.08M399.53M442.67M
Net Income162.19M-32.68M-22.01M3.20M289.98M274.96M
Balance Sheet
Total Assets4.54B4.64B4.01B3.43B2.13B1.82B
Cash, Cash Equivalents and Short-Term Investments369.49M331.50M759.91M1.44B353.61M205.33M
Total Debt377.84M462.12M1.22B767.08M602.17M611.26M
Total Liabilities1.22B1.53B1.67B1.06B1.12B1.10B
Stockholders Equity3.32B3.11B2.34B2.37B1.00B714.60M
Cash Flow
Free Cash Flow0-471.97M-1.13B-439.85M183.70M-46.25M
Operating Cash Flow0-129.97M13.13M18.85M560.51M22.51M
Investing Cash Flow072.52M-527.68M-1.44B-551.68M-122.38M
Financing Cash Flow043.57M446.53M1.52B-9.34M61.81M

Valiant Laboratories Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price103.25

Price Trends

50DMA121.14Negative
100DMA97.24Positive
200DMA81.46Positive

Market Momentum

MACD-4.51Positive
RSI29.00Positive
STOCH-0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VALIANTLAB, the sentiment is Negative. The current price of 103.25 is below the 20-day moving average (MA) of 120.93, below the 50-day MA of 121.14, and above the 200-day MA of 81.46, indicating a neutral trend. The MACD of -4.51 indicates Positive momentum. The RSI at 29.00 is Positive, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VALIANTLAB.

Valiant Laboratories Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:VALIANTLAB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:MEDICAMEQIN:MEDICAMEQ64NeutralINR 3.99B32.55―0.34%27.47%6.56%
IN:MEDICOIN:MEDICO63NeutralINR 1.55B11.25――50.78%20.08%
IN:BAFNAPHIN:BAFNAPH60NeutralINR 11.36B98.77――8.74%31.20%
IN:VALIANTLABIN:VALIANTLAB56NeutralINR 5.61B33.76――102.37%176.45%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ALBERTDAVDIN:ALBERTDAVD54NeutralINR 4.39B15.26―0.64%19.69%―
IN:ZIMLABIN:ZIMLAB53NeutralINR 7.29B256.58――13.14%-60.77%

* General Sector Average

Performance Comparison

0%100%IN:VALIANTLABIN:ALBERTDAVDIN:BAFNAPHIN:MEDICAMEQIN:MEDICOIN:ZIMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:VALIANTLAB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:VALIANTLABValiant Laboratories Ltd.103.2526.0933.81%
IN:ALBERTDAVDAlbert David Ltd770.00-28.20-3.53%
IN:BAFNAPHBafna Pharmaceuticals Limited480.00305.70175.39%
IN:MEDICAMEQMedicamen Biotech Limited293.85-109.34-27.12%
IN:MEDICOMedico Remedies Ltd.18.73-34.59-64.87%
IN:ZIMLABZim Laboratories Ltd.135.8561.6883.16%

Valiant Laboratories Ltd. Corporate Events

Valiant Laboratories to Hold 5th AGM via Video Conferencing with Full E-Voting Access

Aug 31, 2026

Valiant Laboratories Ltd., a Mumbai-based listed pharmaceutical and chemical manufacturer, engages with a broad shareholder base through India’s main stock exchanges. The company’s operations are shaped by stringent regulatory requirements, and it in...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 10, 2026